

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 May 2026

The effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in pain reduction after photorefractive keratectomy (PRK)

Protocol summary

Summary

In this study 50 patients between 18 to 70 years old who are going to have a photorefractive keratotomy (PRK) will be divided into three groups in order to compare the effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in pain reduction after PRK. Patients will be given randomly one of three following drugs: 1) Gabapentin 2) Pregabalin or 3) placebo for 3 days after PRK surgery. The pain will be measured based on VAS (visual analog scale) on the day of operation and on the 3rd day (morning, evening) and then compared among three groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT1138901211180N12**

Registration date: **2010-05-21, 1389/02/31**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2010-05-21, 1389/02/31

Registrant information

Name

pooya rostami

Name of organization / entity

Ophthalmic Research Center

Country

Iran (Islamic Republic of)

Phone

+98 21 2258 5952

Email address

labbafi@hotmail.com

Recruitment status

Recruitment complete

Funding source

Ophthalmic Research Center

Expected recruitment start date

2010-03-05, 1388/12/14

Expected recruitment end date

2010-10-06, 1389/07/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in pain reduction after photorefractive keratectomy (PRK)

Public title

The effect of Gabapentin (Neurentin) and Pregabalin (Lyrica) in pain reduction after photorefractive keratectomy (PRK)

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: patients who are candidate for PRK, age between 18 to 70. Exclusion criteria: using any systemic analgesic drugs, drug intolerance, need of systemic or topical administration of NSAIDs or eye drops for allergy and glaucoma, dry eyes, pregnancy, breast feeding.

Age

From **18 years** old to **70 years** old

Gender

Both

Phase

2-3

Groups that have been masked

No information

Sample size

Target sample size: 50

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

1

Registry name

ClinicalTrials.gov

Secondary trial Id

NCT01122004

Registration date

2010-12-04, 1389/09/13

Ethics committees

1

Ethics committee

Name of ethics committee

Ophthalmic Research Center

Street address

No 23, Pasdaran Ave, 9th Boostan

City

Tehran

Postal code

166666

Approval date

2010-02-22, 1388/12/03

Ethics committee reference number

7527،ج ت

Health conditions studied

1

Description of health condition studied

Refractive errors

ICD-10 code

H52

ICD-10 code description

Disorders of refraction and accommodation

Primary outcomes

1

Description

pain

Timepoint

3rd day

Method of measurement

visual analog scale (VAS)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention: Gabapentin 400mg twice a day for 3 days

Category

Treatment - Drugs

2

Description

Intervention: Pregabalin 75 mg twice a day for 3 days

Category

Treatment - Drugs

3

Description

Contrlo: placebo

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Labbafinejad Hospital

Full name of responsible person

Street address

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ophthalmic Research Center

Full name of responsible person

Ali-Asghar Aghdai

Street address

No 23, Pasdaran Ave, 9th Boostan

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ophthalmic Research Center
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

N0 23, Pasdaran Ave, 9th Boostan, Ophthalmic
Research Center
City
Tehran
Postal code
1666663111
Phone
+98 21 2276 6106
Fax
Email
labbafi@hotmail.com
Web page address

Person responsible for general inquiries

Contact

Name of organization / entity
Ophthalmic Rsearch Center, Shahid Beheshti
University of Medical Sciences
Full name of responsible person
Dr Mohammad Pakravan
Position
Ophthalmologist
Other areas of specialty/work
Street address
No 23, Pasdaran Ave, 9 th Boostan, Ophthalmic
Research Center
City
Tehran
Postal code
166666
Phone
+98 21 2259 2200
Fax
Email
labbafi@hotmail.com
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Ophthalmic Research Center, Shahid Beheshti
University of Medical Sciences
Full name of responsible person
Dr Amir Faramarzi
Position
Ophthalmolgist
Other areas of specialty/work
Street address

Person responsible for updating data

Contact

Name of organization / entity
Ophthalmic Research Center, Shahid Beheshti
University of Medical Sciences
Full name of responsible person
Pooya Rostami
Position
General physician
Other areas of specialty/work
Street address
No 23, Pasdaran Ave, 9th Boostan, Ophthalmic
Research Center
City
Tehran
Postal code
Phone
Fax
Email
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty